Compare Novavax Inc (NVAX) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Raymond James Financial, Inc. — how do they compare? Novavax Inc trades at $7.93 (market cap $1.31B), while Raymond James Financial, Inc. trades at $180.59 (market cap $34.63B). The key difference: Raymond James Financial, Inc. is far larger — about 26.4× Novavax Inc's market cap, and Raymond James Financial, Inc. pays a 1.2% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | RJF | |
|---|---|---|
Market Cap | $1.31B | $34.63B |
Sector | Health | Financials |
52-Week High | $11.19 | $180.55 |
52-Week Low | $6.22 | $140.89 |
Enterprise Value | $889.30M | — |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
Raymond James Financial (RJF) trades at $180.34, up 0.7% for the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust revenue growth, with 2025 revenue at $13.84B and net income of $2.14B, supported by a P/E of 15.69 and net margin of 15.37%. Recent news highlights record Q3 2026 results and a golden cross formation, indicating positive momentum.
Outlook is positive due to consistent earnings outperformance and analyst buy ratings, but risks include volatile cash flows from investing activities and reliance on capital markets strength. The consensus price target of $183.75 suggests modest upside, with institutional interest shown by CalPERS' recent share acquisition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
